A Critical Appraisal of the Updated 2014 Nice Pulmonary Hypertension Classification System

被引:18
|
作者
Lau, Edmund M. T. [1 ,2 ,3 ]
Humbert, Marc [1 ,2 ,4 ]
机构
[1] Hop Bicetre, AP HP, Ctr Reference Hypertens Pulm Severe, DHU Thorax Innovat,Serv Pneumol, Le Kremlin Bicetre, France
[2] Ctr Chirurg Marie Lannelongue, LabEx LERMIT, INSERM UMR S999, Le Plessis Robinson, France
[3] Univ Sydney, Sydney Med Sch, Camperdown, NSW, Australia
[4] Univ Paris 11, Le Kremlin Bicetre, France
关键词
SEROTONIN-REUPTAKE INHIBITORS; ARTERIAL-HYPERTENSION; CLINICAL CLASSIFICATION; VENOOCCLUSIVE DISEASE; PRESSURE-GRADIENT; NITRIC-OXIDE; RISK; THERAPY; SILDENAFIL; DIAGNOSIS;
D O I
10.1016/j.cjca.2014.09.033
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In 2013, the Fifth World Symposium on Pulmonary Hypertension (PH) was held in Nice, France. This meeting has been held every 5 years since the Second World Symposium in 1998, when the modern-day classification system of PH was initially conceived. PH is a pathophysiologic state of the pulmonary circulation characterized by an increased mean pulmonary artery pressure >= 25 mm Hg at rest, and can be the consequence of a variety of distinct disease entities. The rationale of a classification system for PH was to group together disease entities that share similar pathomechanisms, clinical presentation, and therapeutic approaches. Refinements of the classification system have been made at each subsequent World Symposium, reflecting the ongoing research and new knowledge acquired in the science of PH. We provide an update of the recent changes made to the PH classification system from the Nice meeting.
引用
收藏
页码:367 / 374
页数:8
相关论文
共 50 条